In This Article:
Release Date: November 13, 2024
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
Positive Points
-
Bionano Genomics Inc (NASDAQ:BNGO) has significantly reduced operating expenses and cash burn, achieving a 69% decrease in GAAP operating expenses and a 49% decrease in non-GAAP operating expenses compared to the previous year.
-
The company reported a 27% increase in flow cell sales year-over-year, indicating growing utilization among existing customers.
-
Bionano Genomics Inc (NASDAQ:BNGO) has successfully implemented a new go-to-market strategy focusing on high-volume routine users, which is expected to drive future growth in consumables.
-
The company has made progress in reimbursement initiatives, with a new CPT code established for optical genome mapping, potentially increasing adoption and utilization.
-
There is strong demand for the new Stratus system, particularly in key geographies like Europe, the US, Canada, and Israel, which addresses higher throughput needs for customers.
Negative Points
-
Bionano Genomics Inc (NASDAQ:BNGO) experienced a 35% year-over-year decrease in revenue for Q3 2024, partly due to the discontinuation of clinical services products.
-
The company's GAAP gross margin was negative 139% due to one-time charges related to inventory write-downs and discontinued services.
-
The transition to a new operating strategy has resulted in slower growth in the optical genome mapping installed base, with only five net placements in Q3 2024.
-
There are potential additional write-downs of receivables related to discontinued clinical services, which could impact future financial results.
-
Delays in system purchases have affected revenue, and while these processes are ongoing, there is uncertainty about the timing of their completion.
Q & A Highlights
Q: Can you provide an update on the status of the Ionic sample prep system? Is it still slated for launch later this year? A: We have seen amazing data from the Ionic sample prep system, but we do not expect a full commercial rollout this year. The program is progressing well, and demand is high for the system. - Dr. Eric Holman, CEO
Q: What is the growth potential for the 150 target accounts you mentioned? Are they higher volume users, and how do you expect growth to come from them? A: The 150 target accounts include both mature users and those ramping up for routine use. They account for about 80% of consumables revenue. Growth is expected as these labs add more indications, increasing their consumables needs. - Dr. Eric Holman, CEO